Triple-Drug cocktail shows promise in early prostate cancer trial

NCT ID NCT04477512

Completed Disease control Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a combination of three drugs—cabozantinib, abiraterone, and nivolumab—in 18 men with metastatic hormone-sensitive prostate cancer that had not yet been treated. The main goal was to find a safe dose and check for serious side effects. Researchers also looked at whether the treatment could lower PSA levels and shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cabozantinib, abiraterone acetate, nivolumab, and prednisone
What this could lead to: If this combination proves safe and effective, it could offer a new treatment option for men with metastatic hormone-sensitive prostate cancer.
What could go wrong: This is a very early (phase 1) trial with only 18 participants, so results may not apply to everyone. The drug combination also carries risks of serious side effects like immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE REFRACTORY PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC HORMONE REFRACTORY PROSTATE CANCER

Contacts and locations

Locations

Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.